Literature DB >> 26667140

Response to "Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?".

Yibing Ruan1, Aru Narendran1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26667140      PMCID： PMC4677425          DOI： 10.1093/neuonc/nov290

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

1.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

2.  Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?

Authors:  Janki Patel; Cláudia M Salgado; Miguel Reyes Múgica; Dipanjan Basu
Journal:  Neuro Oncol       Date:  2016-01       Impact factor: 12.300

3.  Unraveling the mysteries of IGF-1 signaling in melanoma.

Authors:  John T Lee; Patricia Brafford; Meenhard Herlyn
Journal:  J Invest Dermatol       Date:  2008-06       Impact factor: 8.551

Review 4.  Insulin-like growth factor system and sporadic malignant melanoma.

Authors:  Ettore Capoluongo
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

5.  Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

Authors:  Kathryn Tworkoski; Garima Singhal; Sebastian Szpakowski; Christina Ivins Zito; Antonella Bacchiocchi; Viswanathan Muthusamy; Marcus Bosenberg; Michael Krauthammer; Ruth Halaban; David F Stern
Journal:  Mol Cancer Res       Date:  2011-04-26       Impact factor: 5.852

6.  Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.

Authors:  Jessica L F Teh; Raj Shah; Seung-Shick Shin; Yu Wen; Janice M Mehnert; James Goydos; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2014-04-11       Impact factor: 4.693

Review 7.  Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

Authors:  Daniel V T Catenacci
Journal:  Mol Oncol       Date:  2014-10-18       Impact factor: 6.603

8.  Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) contrasts melanoma progression in vitro and in vivo.

Authors:  Antimo Naspi; Vincenzo Panasiti; Franco Abbate; Vincenzo Roberti; Valeria Devirgiliis; Michela Curzio; Martina Borghi; Francesco Lozupone; Simone Carotti; Sergio Morini; Eugenio Gaudio; Stefano Calvieri; Paola Londei
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240
  8 in total
  1 in total

1.  The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis.

Authors:  Dipanjan Basu; Cláudia M Salgado; Bruce Bauer; Yasmin Khakoo; Janki R Patel; Ryan M Hoehl; Dominique M Bertolini; Joie Zabec; Morgan R Brzozowski; Miguel Reyes-Múgica
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.